All In Biotech

Drug Trial Radar · NCT00623623

STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction

STREAM (Strategic Reperfusion Early After Myocardial Infarction). Comparison of the Efficacy and Safety of a Strategy of Early Fibrinolytic Treatment With Tenecteplase and Additional Antiplatelet and Antithrombin Therapy Followed by Catheterisation Within 6-24 Hours or Rescue Coronary Intervention Versus a Strategy of Standard Primary PCI in Patients With Acute Myocardial Infarction Within 3 Hours of Onset of Symptoms

Last checked: Nov 20, 2026Latest source record: Aug 1, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,899 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,899

Actual

Start

Mar 1, 2008

Primary completion

Sep 1, 2012

Study completion Sep 1, 2012

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Feb 26, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims at evaluating, in a proof of concept approach, the outcome of patients presenting with acute ST-elevation myocardial infarction within 3 hours of symptom onset in either a pre-hospital setting or community hospital emergency room without a PCI facility. Following randomisation a strategy of early tenecteplase and additional antiplatelet and antithrombin therapy followed by catheterisation within 6-24 hours with timely coronary intervention as appropriate (or by rescue coronary intervention if required) in Group A will be compared to primary PCI performed according to local standards in Group B. The study is exploratory in nature and will examine this medical question. The efficacy and safety endpoints as well as mixed (efficacy and safety) composite endpoints up to or before 30 days following randomisation will be evaluated. All clinical endpoints of main interest will be assessed as single or composite endpoints for evaluation of the trial objective. All statistical tests are of exploratory nature based on descriptive p-values for formal statistical hypotheses generation.

Conditions

  • Myocardial Infarction

Interventions

  • primary PCIProcedure

    Standard primary PCI

  • enoxaparinDrug

    Adjunctive treatment

  • catheterisationProcedure

    Routine or rescue coronary intervention

  • tenecteplaseDrug

    Single, weight-adjusted i.v. bolus of tenecteplase

  • clopidogrelDrug

    Adjunctive treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Patients With All-cause Mortality, Cardiogenic Shock, Congestive Heart Failure and Recurrent Myocardial Infarction Within 30 Days for FAS.Time frame: 30 days

Locations

201 sites in 16 countries. Site status is shown where the registry gives one.

  • 1123.28.43009 Boehringer Ingelheim Investigational Site

    Salzburg, Austria

  • 1123.28.43010 Boehringer Ingelheim Investigational Site

    Salzburg, Austria

  • 1123.28.43001 Boehringer Ingelheim Investigational Site

    Vienna, Austria

  • 1123.28.43002 Boehringer Ingelheim Investigational Site

    Vienna, Austria

  • 1123.28.43003 Boehringer Ingelheim Investigational Site

    Vienna, Austria

  • 1123.28.43004 Boehringer Ingelheim Investigational Site

    Vienna, Austria

  • 1123.28.43005 Boehringer Ingelheim Investigational Site

    Vienna, Austria

  • 1123.28.43007 Boehringer Ingelheim Investigational Site

    Vienna, Austria

  • 1123.28.43008 Boehringer Ingelheim Investigational Site

    Vienna, Austria

  • 1123.28.32060 Boehringer Ingelheim Investigational Site

    Bornem, Belgium

  • 1123.28.32010 Boehringer Ingelheim Investigational Site

    Brussels, Belgium

  • 1123.28.32070 Boehringer Ingelheim Investigational Site

    Herentals, Belgium

  • 1123.28.32040 Boehringer Ingelheim Investigational Site

    Liège, Belgium

  • 1123.28.55010 Boehringer Ingelheim Investigational Site

    Brasília, Brazil

  • 1123.28.55020 Boehringer Ingelheim Investigational Site

    Brasília, Brazil

  • 1123.28.55008 Boehringer Ingelheim Investigational Site

    Cabo Frio, Brazil

  • 1123.28.55017 Boehringer Ingelheim Investigational Site

    Campinas, Brazil

  • 1123.28.55007 Boehringer Ingelheim Investigational Site

    Porto Alegre, Brazil

  • 1123.28.55001 Boehringer Ingelheim Investigational Site

    Recife, Brazil

  • 1123.28.55018 Boehringer Ingelheim Investigational Site

    Rio de Janeiro, Brazil

  • 1123.28.55028 Boehringer Ingelheim Investigational Site

    Rio de Janeiro, Brazil

  • 1123.28.55016 Boehringer Ingelheim Investigational Site

    Sao Lourenço Do Sul, Brazil

  • 1123.28.55004 Boehringer Ingelheim Investigational Site

    São Paulo, Brazil

  • 1123.28.55014 Boehringer Ingelheim Investigational Site

    São Paulo, Brazil

  • 1123.28.11006 Boehringer Ingelheim Investigational Site

    Edmonton, Alberta, Canada

  • 1123.28.11505 Boehringer Ingelheim Investigational Site

    Edmonton, Alberta, Canada

  • 1123.28.11002 Boehringer Ingelheim Investigational Site

    Newmarket, Ontario, Canada

  • 1123.28.13001 Boehringer Ingelheim Investigational Site

    Santiago, Chile

  • 1123.28.13002 Boehringer Ingelheim Investigational Site

    Santiago, Chile

  • 1123.28.13003 Boehringer Ingelheim Investigational Site

    Santiago, Chile

  • 1123.28.13004 Boehringer Ingelheim Investigational Site

    Santiago, Chile

  • 1123.28.13005 Boehringer Ingelheim Investigational Site

    Santiago, Chile

  • 1123.28.13006 Boehringer Ingelheim Investigational Site

    Santiago, Chile

  • 1123.28.3376A Boehringer Ingelheim Investigational Site

    Ambérieu-en-Bugey, France

  • 1123.28.3329A Boehringer Ingelheim Investigational Site

    Aubervilliers, France

  • 1123.28.3329B Boehringer Ingelheim Investigational Site

    Aubervilliers, France

  • 1123.28.3329C Boehringer Ingelheim Investigational Site

    Aubervilliers, France

  • 1123.28.3315A Boehringer Ingelheim Investigational Site

    Besançon, France

  • 1123.28.3315B Boehringer Ingelheim Investigational Site

    Besançon, France

  • 1123.28.3351A Boehringer Ingelheim Investigational Site

    Besançon, France

Showing 40 of 201 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.